2025/01/01 by Elisa J. Gordon, Michael K. Gusmano, Jessica Gacki‐Smith +5 · 7 citations
paper · doi:10.1111/xen.70016
published in Xenotransplantation 32(1) (Wiley)
crossref issued 2025/01/01 · crossref published 2025/01/01 · crossref published-print 2025/01/01 · crossref published-online 2025/02/24 · crossref created 2025/02/26 · crossref deposited 2025/12/01 · crossref indexed 2026/08/04
ABSTRACT Background Transplant programs preparing to initiate first‐in‐human pig kidney xenotransplant clinical trials must be especially careful when obtaining participants’ informed consent. Little is known about the kind of information patients want for making an informed decision about trial participation. Methods We conducted semi‐structured telephone interviews with waitlisted kidney transplant patients about information needs regarding participating in a first‐in‐human pig kidney xenotransplant trial, which guided development of a prototype consent form. Subsequent usability testing interviews sought patient feedback on the consent form. We analyzed qualitative data by thematic analysis and quantitative data by descriptive statistics. Results Twenty‐eight patients participated in semi‐structured interviews; 16 patients participated in usability testing interviews. Most interview participants were male (68%, 56%), White (54%, 56%), or Black (36%, 31%), respectively. Interview participants identified five types of information needs: (1) the potential for infection contraction and transmission; (2) risks, benefits, and impact of xenotransplant trials; (3) xenotransplant clinical trial and recipient experience; (4) clinical trial logistics; and (5) the pig and its kidney. Usability testing participants suggested adding details to the prototype. Participants’ preparedness to make a decision about participating in a xenotransplant trial increased after reviewing the prototype (12.5% vs. 31.3%, n.s.). Conclusion We identified multiple unique types of information patients desired to make informed decisions about pig kidney xenotransplant trial participation. Transplant programs initiating xenotransplant trials should be prepared to address patients’ information needs to optimize informed decision‐making for trial participation. The prototype consent form may support a patient‐centered approach to informed consent.